Liver cancer: etiology, pathogenesis, results of long-term clinical and epidemiological observation

Chekmazov, I A; Ivanikov, Igor O.; Сапронов, Г. В.; Kirillova, N. Ch.; Виноградова, Н. Н.

doi:10.17116/dokgastro201980115

Cited by 4 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…E. Mukhin 1 , Yu. S. Konstantinova 1 , R. R. Gimadiev 2 , N. V. Mazurchik 2 1 Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical Biological Agency, 119435, Moscow, Russia 2 Federal State Autonomous Educational Institution for Higher Education "Peoples' Friendship University of Russia", 117198, Moscow, Russia https://doi.org/10.31146/1682-8658-ecg-191-7-…-……”

Section: Horizons Of Development Of Immunotherapy For Malignant Liver Tumorsmentioning

confidence: 99%

“…Первичные опухоли печени и внутрипеченочных желчных протоков являются одним из наиболее распространенных типов злокачественных новообразований, характеризующихся постоянно растущим уровнем смертности, поздней диагностикой и агрессивным течением, что обусловливает крайне неблагоприятный прогноз [1]. Данная группа заболеваний включает гепатоцеллюлярную карциному (ГЦК), внутрипеченочную и внепеченочную холангиокарциному, рак желчного пузыря.…”

Section: Introductionunclassified

“…Гепатоцеллюлярная карцинома является злокачественной эпителиальной опухолью, возникающей из гепатоцитов, и на её долю приходится 70-85% случаев всех первичных опухолей печени. Развитие ГЦК ассоциируется с циррозом печени, вызванным вирусными гепатитами В и С, хроническим злоупотреблением алкоголем [1]. Метаболические нарушения, такие как диабет, ожирение и неалкогольная жировая болезнь печени, также являются факторами риска для развития ГЦК [2].…”

Section: Introductionunclassified

“…Кроме того, даже если лечение проведено по радикальной программе, риск рецидива остается крайне высоким [1]. В связи с этим, не прекращается поиск новых стратегий терапии злокачественных новообразований печени, отличных от традиционных методов лечения.…”

Section: Introductionunclassified

See 3 more Smart Citations

Horizons of development of immunotherapy for malignant liver tumors

Мухин

Константинова

Гимадиев

et al. 2021

jour

View full text Add to dashboard Cite

Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is still the most effective treatment in the early stages of the disease, however in most cases early diagnosis is difficult. Moreover, even if the treatment is carried out according to a radical program, the risk of relapse remains extremely high. In this regard, the search for new strategies for the treatment of liver malignancies that differ from traditional methods of treatment is not terminated. One of such promising approaches is immunotherapy. The present review is devoted to the current understanding of the mechanisms of action and the available clinical experience in the use of immunotherapy approaches in the treatment of liver malignancies. Combining different types of immunotherapy or combining immunotherapy with traditional therapeutic approaches can facilitate a synergistic effect and contribute to the development of personalized medicine.

show abstract

Section: Horizons Of Development Of Immunotherapy For Malignant Liver Tumorsmentioning

confidence: 99%

Section: Introductionunclassified

See 2 more Smart Citations

Horizons of development of immunotherapy for malignant liver tumors

Мухин

Константинова

Гимадиев

et al. 2021

jour

View full text Add to dashboard Cite

show abstract

“…Low rates were in Algeria, India, Belgium and the Netherlands. In Russia 61.5% of patients die of liver cancer progression in the first year after diagnosis [1,2].Information on the global burden of cancer in 2018 showed that the specific weight of liver cancer in the structure of malignant neoplasms (MN) is 8.2%, and in 2020 -8.3% [3].The worldwide peculiarity of liver cancer is its late diagnosis. Several evidence-based treatment options for liver cancer are currently available: liver transplantation for hepatocellular liver cancer (HCC) (according to the Milan criteria), radiofrequency ablation as a radical treatment option (RFA), chemoembolization for intrahepatic cholangiocarcinoma (TACE), and the administration of Sorafenib as systemic therapy [4].Current approaches for the treatment of early-stage primary liver cancer are represented by hepatic RFA, and the efficacy of this approach depends on the subjective attentiveness and visual acuity of the clinician.…”

mentioning

confidence: 99%

Actual issues of secondary prevention of liver cancer in Kazakhstan

Malayev,

Saparbayev,

Kubekova

et al. 2023

J CLIN MED KAZ

View full text Add to dashboard Cite

Liver cancer is characterized by high mortality and low survival rates in most countries of the world. According to the WHO data, more than 1.3 million people with liver cancer die annually in the world and according to the data of the 9th volume of "Cancer on five continents" - the highest standardized incidence rates are in Korea - 44.9 per 100 thousand population as well as in Thailand, Japan, China. Low rates were in Algeria, India, Belgium and the Netherlands. In Russia 61.5% of patients die of liver cancer progression in the first year after diagnosis [1,2]. Information on the global burden of cancer in 2018 showed that the specific weight of liver cancer in the structure of malignant neoplasms (MN) is 8.2%, and in 2020 - 8.3% [3].   The worldwide peculiarity of liver cancer is its late diagnosis. Several evidence-based treatment options for liver cancer are currently available: liver transplantation for hepatocellular liver cancer (HCC) (according to the Milan criteria), radiofrequency ablation as a radical treatment option (RFA), chemoembolization for intrahepatic cholangiocarcinoma (TACE), and the administration of Sorafenib as systemic therapy [4]. Current approaches for the treatment of early-stage primary liver cancer are represented by hepatic RFA, and the efficacy of this approach depends on the subjective attentiveness and visual acuity of the clinician. The latest technique used in liver RFA is the hyperspectral imaging which utilize objective assessment [2]. Ultrasound is usually used to detect liver lesions, but the detection rate is low for many reasons, such as clinician skills and technical capabilities. Modern approaches of diagnostic capabilities, such as contrast-enhanced ultrasound integrated imaging (CEUS) and comprehensive ultrasound imaging - contrast-enhanced CT (CECT) or contrast-enhanced MRI (CEMRI) for visualization of focal liver lesions (FLL) - increase the confidence of the interventional physician so it should be recommended for use as a routine procedure [5-6]. The ratio of morbidity and mortality in many countries reaches 91.6%, which represents the third most important cause of cancer deaths [7-9].

show abstract

Impact of hepatocellular cancer screening on early diagnostics and overall survival: own data

Petkau,

Bessonova,

Tarkhanov

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. An increase in the life expectancy of patients with HCC can be achieved both by improving treatment methods and by implementing early examination through screening programs.Aim. Evaluation of the impact of screening in risk groups on early detection of HCC, on the possibility of specialized treatment, on one-year overall survival of patients with HCC.Materials and methods. The clinical records of 148 patients with HCC and liver cirrhosis (LC) who received medical care at the Sverdlovsk Regional Oncology Center in 2022 with the follow-up period exceeding 12 months were retrospectively studied. HCC was diagnosed as a result of screening carried out on the basis of the Regional Hepatological Center in 34 patients. 114 patients were referred to the oncological hospital due to the detection of a malignant tumor in liver during examination in cause of complaints. The compared groups of patients did not differ in age and sex composition, in the frequency of smoking, alcohol consumption, drug addiction, viral hepatitis B, obesity, diabetes mellitus, arterial hypertension, oncological heredity, in the distribution of LC by class. Patients with HCC detected at screening had a better general somatic status (p < 0.001), more often had viral hepatitis C (82.4% vs. 35.1%, p < 0.001) and AFP above normal (64.7% vs. 43.0%, p = 0.027).Results. Screening influenced the staging of newly diagnosed patients with HCC. If the proportion of stages B and C according to the Barcelona system remained the same, then stage A accounted for 32.4% versus 12.3% (OR = 3.42; 95% CI 1.37–8.49; p = 0.007). Stage D, on the contrary, was less: 8.8% vs. 36.8% (OR = 0.17; 95% CI 0.05–0.58; p = 0.002). Identification at earlier stages and better general condition of patients influenced the possibilities and results of treatment. In the HCC group after screening more patients received treatment: 88.2% versus 56.1% (OR = 5.86; 95% CI 1.94–17.73; p < 0.001). There was a higher one-year overall survival: 79.4% vs 39.5% (OR = 5.91; 95% CI 2.38–14.73; p < 0.001).Conclusion. Screening for HCC in risk groups improves early diagnosis, increases the likelihood of patients receiving specialized anticancer treatment and increases the one-year overall survival rate.

show abstract

Liver cancer: etiology, pathogenesis, results of long-term clinical and epidemiological observation

Cited by 4 publications

References 11 publications

Horizons of development of immunotherapy for malignant liver tumors

Horizons of development of immunotherapy for malignant liver tumors

Actual issues of secondary prevention of liver cancer in Kazakhstan

Impact of hepatocellular cancer screening on early diagnostics and overall survival: own data

Contact Info

Product

Resources

About